Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlate with clinicopathological parameters.
An extended analysis for loss of heterozygosity (LOH) on eight chromosomes was conducted in a series of 82 Wilms tumors. Observed rates of allele loss were: 9.5% (1p), 5% (4q), 6% (6p), 3% (7p), 9.8% (11q), 28% (11p15), 13.4% (16q), 8.8% (18p), and 13.8% (22q). Known regions of frequent allele loss on chromosome arms 1p, 11p15, and 16q were analyzed with a series of markers, but their size could not be narrowed down to smaller intervals, making any positional cloning effort difficult. In contrast to most previous studies, several tumors exhibited allele loss for multiple chromosomes, suggesting an important role for genome instability in a subset of tumors. Comparison with clinical data revealed a possible prognostic significance, especially for LOH on chromosome arms 11q and 22q with high frequencies of anaplastic tumors, tumor recurrence, and fatal outcome. Similarly, LOH 16q was associated with anaplastic and recurrent tumors. These markers may be helpful in the future for selecting high-risk tumors for modified therapeutic regimens.
Physiologische Chemie I, Theodor-Boveri-Institut für Biowissenschaften, Universität Würzburg, Am Hubland, Germany.
B
B
Klamt
M
M
Schulze
C
C
Thäte
J
J
Mares
P
P
Goetz
R
R
Kodet
W
W
Scheulen
A
A
Weirich
N
N
Graf
M
M
Gessler
D000483:Alleles; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002877:Chromosomes, Human / Q000187:drug effects / Q000235:genetics*; D002880:Chromosomes, Human, Pair 11 / Q000187:drug effects / Q000235:genetics; D002885:Chromosomes, Human, Pair 16 / Q000187:drug effects / Q000235:genetics; D002892:Chromosomes, Human, Pair 22 / Q000187:drug effects / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D019656:Loss of Heterozygosity / Q000187:drug effects / Q000235:genetics*; D009396:Wilms Tumor / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*
D000970:Antineoplastic Agents